Zhenyuan Wang,ab Mi Wang, *a Qingsheng Tao,c Yufei Li, d Hao Wang,a Mei Zhang,c Xueli Liuc and Jiaheng Zhang *a
a Sauvage Laboratory for Smart Materials, School of Materials Science and Engineering, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China. E-mail: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。, 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
b Shenzhen Shinehigh Innovation Technology Co., Ltd., Shenzhen 518055, China
c Advanced Research, L'Oreal Research & Innovation China, Shanghai 201206, China
d The Centre in Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao 999078, China
† Electronic supplementary information (ESI) available. CCDC 2101906. For ESI
and crystallographic data in CIF or other electronic format see DOI: https://doi.
org/10.1039/d5md00001g
Salicylic acid (SA) is a natural lipophilic active ingredient commonly used in cosmetics and skin disease treatments, offering benefits such as exfoliation, anti-inflammation effects, antibacterial properties, oil control, and acne alleviation. However, its poor water solubility, low bioavailability, and potential side effects, such as allergies, irritation, and dryness, hinder its widespread application. In this study, we prepared a betaine–salicylic acid (BeSA) cocrystal and systematically characterized its crystal structure, biological activity, and clinical efficacy. The results showed that BeSA has significantly lower irritancy and cytotoxicity than SA, but exhibits excellent anti-inflammatory and antioxidant properties as well as high moisturizing and anti-acne efficacy, making it a potential alternative to SA. Further, quantum chemical calculations and molecular docking simulations were conducted to investigate the intrinsic mechanisms underlying the excellent bioactivity of BeSA cocrystals. This study introduces an innovative solution for safer and more effective skincare formulations based on SA and offers theoretical guidance regarding material engineering and further material optimization, which has crucial implications for both industry and academia.
Received 1st January 2025,
Accepted 4th February 2025
DOI: 10.1039/d5md00001g rsc.li/medchem
Anna Ericsson a,* , Karin Borgstrom¨ b,c , Christine Kumlien a,c,d , Magdalena Gershater Annersten a,c , Tautgirdas Ruzgas b,c , Johan Engblom b,c , Petri Gudmundsson b,c , Victoria Lazer a , Skaidre Jankovskaja b,c , Eva Lavant b,c , Sophia Ågren-Witteschus d , Sebastian Bjorklund ¨ b,d , Saman Salim e,f , Mikael Åstrom¨ g , Stefan Acosta f
a Department of Care Science, Faculty of Health and Society, Malm¨ o University, Malm¨ o, Sweden
b Department of Biomedical Science, Faculty of Health and Society, Malm¨ o University, Malm¨ o, Sweden
c Biofilms – Research Center for Biointerfaces, Malm¨ o University, Malm¨ o, Sweden
d Department of Cardiothoracic and Vascular Surgery, Skåne University Hospital, Malm¨ o, Sweden
e Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark
f Department of Clinical Sciences, Lund University, Malmo, ¨ Sweden
g StatCons, Sweden
ARTICLE INFO
Keywords: Diabetes mellitus Dry feet Prevention Foot-xerosis Self-care
ABSTRACT
Introduction: To minimize the risk of developing foot-ulcers, persons with diabetes are given the advice to daily inspect their feet and to apply skincare formulations. However, commercially available skincare products have rarely been developed and evaluated for diabetes foot care specifically. The primary aim of this randomized controlled trial (RCT) is to evaluate the effects in reducing foot xerosis in persons with diabetes without footulcers using two skincare creams containing different humectants (interventions) against a cream base nonhumectant (comparator). Secondary outcomes are to evaluate differences on skin barrier integrity, lowmolecular weight biomarkers and skin microbiota, microcirculation including transcutaneous oxygen pressure, degree of neuropathy, and HbA1c between intervention-comparator creams.
Methods: Two-armed double-blind RCT, registered in ClinicalTrials.gov Identifier: NCT06427889. With 80 % power, two-tailed significance of 2.5 % in each arm, 39 study persons is needed in each arm, total 78 persons, 98 including dropouts, to be able to prove a reduction of at least one category in the Xerosis Severity Scale with the intervention creams compared to the comparator. In one arm, each participant will treat one foot with one of the intervention creams (Oviderm® or Canoderm®), while the opposite foot will be treated with the comparator cream (Decubal®lipid cream), twice a day. If needed, participants are enrolled after a wash-out period of two weeks. The participants will undergo examinations at baseline, day 14 and day 28.
Discussion: This RCT evaluate the potential effects of humectants in skin creams against foot xerosis in persons with diabetes.
伤口、造口、失禁护理俱乐部
伤口世界平台生态圈，以“关爱人间所有伤口患者”为愿景，连接、整合和拓展线上和线下的管理慢性伤口的资源，倡导远程、就近和居家管理慢性伤口，解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考，最终以医院当日公布为准。
网友、医生言论仅代表其个人观点，不代表本站同意其说法，请谨慎参阅，本站不承担由此引起的法律责任。
